Literature DB >> 8383181

Induction of neutralizing antibodies by varicella-zoster virus gpII glycoprotein expressed from recombinant vaccinia virus.

M Massaer1, M Haumont, M Place, A Bollen, P Jacobs.   

Abstract

The gpII glycoprotein of varicella-zoster virus (VZV) was produced in CV1 cells via vaccinia virus recombinants. Two different DNA constructs were expressed: the first one encodes the complete gpII protein (gpII s+a+) and the second a truncated species lacking the membrane anchorage domain (gpII s+a-). To achieve expression both coding sequences had to be engineered at the 5' end by substituting the unusually short (24 bp) natural signal sequence by a more conventional one encoding 29 amino acids. Recombinant gpII proteins were detected in vaccinia virus-infected cells by ELISA and immunoprecipitation. Both forms of recombinant gpII proteins were produced as glycosylated single-chain molecules of respectively 110K and 90K. Upon reduction these were only partially converted into subunits. A rabbit infected with the vaccinia virus recombinant expressing the complete gpII produced antibodies which recognized VZV antigens and neutralized VZV infectivity in vitro, independent of complement.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383181     DOI: 10.1099/0022-1317-74-3-491

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  2 in total

1.  B-cell epitopes of varicella-zoster virus glycoprotein II.

Authors:  A Kjartansdóttir; E Lycke; S R Norrby
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

2.  Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.

Authors:  Nicole L Sullivan; Morgan A Reuter-Monslow; Janet Sei; Eberhard Durr; Carl W Davis; Cathy Chang; Megan McCausland; Andreas Wieland; David Krah; Nadine Rouphael; Aneesh K Mehta; Mark J Mulligan; Bali Pulendran; Rafi Ahmed; Kalpit A Vora
Journal:  J Virol       Date:  2018-06-29       Impact factor: 6.549

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.